Daclatasvir is an antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It is available as a generic drug and is marketed under brand names such as Daklinza. In Hong Kong, Daclatasvir is a prescription-only medication regulated by the Pharmacy and Poisons Board.
Daclatasvir belongs to a class of antivirals called NS5A inhibitors. The NS5A protein is essential for HCV replication and assembly of new viral particles. By binding to NS5A, Daclatasvir disrupts:
These actions lead to a rapid decline in viral load. Onset of antiviral activity occurs within hours of the first dose, with peak plasma concentrations reached about 2-4 hours after oral administration of the 60 mg pill. The drug is metabolized primarily by CYP3A4 and has a half-life of roughly 12-15 hours, supporting once-daily dosing.
Daclatasvir is approved (by the FDA, EMA, and the Hong Kong Pharmacy and Poisons Board) for use in combination with other direct-acting antivirals to treat chronic hepatitis C infection. Typical approved regimens include:
The medication is not indicated as monotherapy for hepatitis C; it must be used with at least one other antiviral agent to achieve a sustained virologic response (SVR).
If you fall into any of these categories, a healthcare professional should assess suitability on an individual basis.
Patients should disclose all prescription medicines, over-the-counter products, supplements, and herbal remedies to their provider before starting Daclatasvir.
This article provides educational information about Daclatasvir and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Therapeutic courses usually last 12 weeks when combined with sofosbuvir, though shorter (8-week) or longer (24-week) regimens may be prescribed depending on genotype, presence of cirrhosis, and prior treatment history.
Yes, most non-prescription analgesics (e.g., acetaminophen, ibuprofen) do not have known interactions with Daclatasvir, but always verify with a pharmacist, especially if you are using multiple medications.
Regular monitoring of liver enzymes and HCV RNA levels is recommended to track treatment response and detect any hepatic adverse effects early.
When used with appropriate companion antivirals, Daclatasvir has demonstrated efficacy against genotypes 1, 2, 3, and 4. Its activity against genotype 5 or 6 is limited and generally requires alternative regimens.
St. John’s wort is a strong CYP3A inducer and can significantly lower Daclatasvir concentrations, potentially leading to treatment failure. Avoid this herb while on therapy.
Daclatasvir targets the NS5A protein, whereas Sofosbuvir inhibits the NS5B polymerase. They are often combined because their complementary mechanisms enhance viral clearance and reduce resistance risk.
Yes, but keep the medication in its original labeled container, carry a copy of your prescription, and be aware of any import restrictions for pharmaceuticals in the destination country.
Take the missed dose as soon as you remember that day; if it’s already close to the next scheduled dose, skip the missed one and resume the normal once-daily schedule. Do not double-dose.
Co-administration with certain antiretrovirals (e.g., efavirenz) may affect drug levels. A clinician should review the full medication list to adjust any accompanying HIV regimen if needed.
Coverage varies by public versus private insurance plans. Patients should consult their health insurance provider or the Hospital Authority for specific reimbursement information.
